=============================================================================
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON D.C. 20549
FORM 12b-25
NOTIFICATION OF LATE FILING
Commission File Number: 000-29171
(Check One):
[ X ] Form 10-K and Form 10-KSB
[ ] Form 11-K
[ ] Form 20-F
[ ] Form 10-Q and Form 10-QSB
[ ] Form N-SAR
For Period Ended: 09/30/2005
[ ] Transition Report on Form 10-K and Form 10-KSB
[ ] Transition Report on Form 20-F
[ ] Transition Report on Form 11-K
[ ] Transition Report on Form 10-Q and Form 10-QSB
[ ] Transition Report on Form N-SAR
For the Transition Period Ended:
_____________________________________________________________________________
Read Attached Instruction Sheet Before Preparing Form. Please Print or Type.
Nothing in this form shall be construed to imply that the Commission has
verified any information contained herein.
If the notification relates to a portion of the filing checked above,
identify the Item(s) to which the notification relates:
=============================================================================
PART I
REGISTRANT INFORMATION
Full Name of Registrant: MED GEN INC
Former Name if Applicable: N/A
Address of Principal Executive Office: 7284 W PALMETTO ROAD, SUITE 207
City, State and Zip Code: BOCA RATON, FLORIDA 33422
Phone Number: 561-750-1100
PART II
RULE 12b-25(b) AND (c)
If the subject report could not be filed without unreasonable effort or
expense and the Registrant seeks relief pursuant to Rule 12b-25(b), the
following should be completed.
(Check box if appropriate)
[X] (a) The reasons described in reasonable detail in Part III of
this form could not be eliminated without unreasonable effort or expense.
[X] (b) The subject annual report, semi-annual report, transition
report on Form 10-K, 10-KSB, 20-F, 11-K or Form N-SAR, or portion thereof
will be filed on or before the 15th calendar day following the prescribed
due date; or the subject quarterly report or transition report on Form 10-Q,
10-QSB or portion thereof will be filed on or before the fifth calendar day
following the prescribed due date; and
[ ] (c) The accountant's statement or other exhibit required by
Rule 12b-25(c) has been attached if applicable.
PART III
NARRATIVE
State below in reasonable detail the reasons why Form 10-K, 10-KSB,
11-K, 20-F, 10-Q, 10-QSB, N-SAR or the transition report portion thereof
could not be filed within the prescribed time period. (Attach extra sheets
if needed).
Med-Gen, Inc. is requesting this extension because we are waiting for
supporting documents in order to complete the September 30, 2005, audit. The
Company has been advised by its accountant's that several convertible
debentures that were sold to accredited investors during the fiscal year
contain language that requires additional derivative accounting computations.
The Company has retained an expert firm to prepare these calculations and
incorporate them into the filing. This information is required for the
completion of the audit and certain portions of the report 10-KSB.
By: /s/Paul B. Kravitz
---------------------------
Paul B. Kravitz
Chief Executive Officer
PART IV
OTHER INFORMATION
(1) Name and telephone number of person to contact in regard
to this notification:
Paul B. Kravitz 561-750-1100
- ---------------- ------------------------------
(Name) (Area Code) (Telephone Number)
(2) Have all other periodic reports required under section
13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of
the Investment Company Act of 1940 during the preceding 12 months or
for such other shorter period that the Registrant was required to file
such report(s) been filed? If the answer is no, identify report(s).
[x] Yes [ ] No
(3) Is it anticipated that any significant change in results of
operations from the corresponding period for the last fiscal year will
be reflected by the earnings statements to be included in the subject
report or portion thereof?
[] Yes [x] No
If so: attach an explanation of the anticipated change, both narratively
and quantitatively, and, if appropriate, state the reasons why a reasonable
estimate of the results cannot be made.
Med-Gen, Inc.
--------------------------------------------
[Name of Registrant as Specified in Charter]
Has caused this notification to be signed on its behalf by the undersigned
thereunto duly authorized.
Date: December 29, 2005 By: /s/Paul B. Kravitz
---------------------------
Paul B. Kravitz
Chief Executive Officer